IQV Stock IQVIA Holdings Inc - Complete Overview

Nyse / Business Services / Healthcare / IQV Stock

IQVIA Holdings Inc (IQV) price per share as of 24 May 2018
Your sentiment
Shares Outstanding 207.68M
Avg Daily Volume 1.18M
Market Cap 20.56B
Volatility 19.54% LOW


IQV stock is a business services company traded on Nyse. It is valued at 20.56B US dollars. There are 207.68M shares outstanding which IQVIA Holdings Inc issued to investors. Volatility of the stock is LOW, and the daily volume is 19.54% stock on average. It brought investors a total return of 18.30% over the last 12 months. IQVIA Holdings Inc stock is relatively cheap. It's P/E ratio is below the market average.



Earnings Per Share 6.02
Dividends Per Share 0.00
12 Months Price Performance High
Total Return High


IQVIA shares drop 4% after FDA raises 'serious concerns' with its data

IQVIA Holdings Inc. shares dropped 4.5% in extremely heavy Wednesday afternoon trade before being halted on Wednesday after the Food and Drug Administration raised serious concerns with the company's data, which tracks the amount of pharmaceuticals sold in the U.S., and in particular data related to controlled substances like prescription fentanyl. While doing an analysis, the regulator said it discovered a more than 20% discrepancy between the amount of prescription fentanyl actually sold in the U.S. over the last five years and IQVIA's database. After conducting an investigation and speaking with the company, the FDA said that past prescription fentanyl data were overestimated because of an error in the company's methods, likely related to using the wrong conversion factors to figure out how much fentanyl is in a given unit. The overestimation for fentanyl distributed in the U.S. marketplace was specific to estimated volume in kilograms, the regulator said, information the FDA uses "only narrowly," in quota recommendations made to the Drug Enforcement Administration. But the error also extends to several other controlled substances, such as oxymorphone and hydrocodone, raising "serious concerns about systemic issues with IQVIA's data and quality control procedures," the FDA said. IQVIA is now conducting a review to ensure estimates are accurate, but the FDA is also asking it to hire a third-party auditor and give more insight into how its data is generated. IQVIA also recently announced a secondary public offering of 10 million shares at a price of $101.85 per share, along with plans to buy back 2.5 million shares, an offering that's expected to close on Friday. IQVIA shares have declined 4.2% over the last three months, compared with a 0.3% decline in the S&P 500 and a 1.8% drop in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit for more information on this news.

IQVIA Holdings Delivers on Its Promises

Business is booming for the healthcare services provider.

IQVIA Holdings Ends 2017 Strong, Shares Bullish Guidance

The leading provider of services and data for the life sciences industry posted double-digit gains in revenue and profits.

Should You Buy IQVIA (IQV) Ahead of Earnings?

IQVIA (IQV) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

These 3 Stocks Grew 30% in 2017, and They Aren't Slowing Down

Don't let surging share prices fool you into thinking that these three gems can't move higher.


Name Value Action
RSI(14) 56.28 Buy
CMO(14) 12.57 Buy
ADX(14) 17.50 Neutral
Williams %R -17.82 Sell


IQV Industry Sector Market
Price to Earnings 16.45 59.44 32.99 29.19
Price to Book Value 2.51 4.24 6.10 3.43
Price to Sales 2.06 3.40 7.91 3.27
Return on Equity 16.80% 14.08% 20.87% 15.27%
Return on Assets 5.80% 6.16% 8.69% 5.75%
All values TTM (trailing twelve months). Source: